H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Corium (NASDAQ: CORI) today and set a price target of $13. The company’s shares opened today at $9.29.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of -1.2% and a 49.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Corium has an analyst consensus of Moderate Buy, with a price target consensus of $14.
See today’s analyst top recommended stocks >>
Based on Corium’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $18.01 million. In comparison, last year the company had a GAAP net loss of $11.04 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CORI in relation to earlier this year. Last month, Peter Staple, the President & CEO of CORI bought 23,586 shares for a total of $50,002.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA.
